BD (NYSE: BDX) reshapes segments as Mike Garrison plans retirement
Rhea-AI Filing Summary
Becton, Dickinson and Company announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, plans to retire after more than 20 years with BD, effective October 2. He will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next president of the Medical Essentials segment. To streamline the operating model, the BioPharma Systems segment will report directly to Chairman, CEO and President Thomas E. Polen, reflecting its strategic importance as a growth driver.
BD describes itself as one of the world’s largest pure-play medical technology companies, operating globally with more than 60,000 employees and delivering billions of products annually across medical essentials, connected care, biopharma systems and interventional therapies.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Retirement effective date: October 2
Tenure at BD: more than 20 years
Employees: more than 60,000
3 metrics
Retirement effective date
October 2
Effective retirement date for Dr. Michael Garrison after more than 20 years at BD
Tenure at BD
more than 20 years
Length of service of Dr. Michael Garrison before retirement
Employees
more than 60,000
Number of employees worldwide described for BD
Key Terms
Regulation FD, Emerging growth company, Inline XBRL, BioPharma Systems segment, +1 more
5 terms
Regulation FD regulatory
"Item 7.01 Regulation FD disclosure relating to the matters described"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
BioPharma Systems segment financial
"BioPharma Systems segment will report directly to Thomas E. Polen"
Medical Essentials segment financial
"search is underway to identify the next President of the Medical Essentials segment"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive leadership change did BD (BDX) announce?
BD announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, plans to retire. He has held multiple senior roles over more than 20 years with the company, including leadership of BD’s Medical segment and key business units.
When will BD (BDX) executive Mike Garrison retire and how long has he served?
BD states that Mike Garrison will retire effective October 2 after more than 20 years with the company. He joined BD in 2005 and has since held several leadership positions across Medication Management Solutions, Surgery and the broader Medical segment.
How will BD (BDX) reorganize reporting for the BioPharma Systems segment?
BD states that BioPharma Systems will report directly to Chairman, CEO and President Thomas E. Polen. This change is described as streamlining the operating model and reflecting BioPharma Systems’ strategic importance as a growth driver within BD’s global medical technology portfolio.
What is BD (BDX) doing to find a new leader for the Medical Essentials segment?
BD explains that a comprehensive search is underway to identify the next president of the Medical Essentials segment. Garrison will remain in his current role through the end of the fiscal year to support a smooth leadership transition during this recruitment process.
How did BD (BDX) communicate Mike Garrison’s retirement to investors?
BD furnished a press release dated July 22, 2026 as an exhibit, describing Garrison’s planned retirement and related organizational changes. The company notes this information is provided under Regulation FD and is not deemed filed for liability purposes under the Exchange Act.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 19, 2026
| (Exact Name of Registrant as Specified in Its Charter) | ||||||||||||||
| (State or Other Jurisdiction of Incorporation) | ||||||||||||||
| (Commission File Number) | (IRS Employer Identification No.) | |||||||||||||
| | ||||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
(Registrant’s Telephone Number, Including Area Code) | |||||||||||||||||
N/A | |||||||||||||||||
(Former Name or Former Address, if Changed Since Last Report) | |||||||||||||||||
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | |||||
Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Dr. Garrison will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next President of the Medical Essentials segment. Going forward, to streamline BD's operating model, the BioPharma Systems segment will report directly to Thomas E. Polen, Chairman, CEO and President of BD.
Item 7.01 REGULATION FD DISCLOSURE
On July 22, 2026, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 Press release dated July 22, 2026 which is furnished pursuant to Item 7.01.
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BECTON, DICKINSON AND COMPANY
(Registrant)
| By: | /s/ Stephanie M. Kelly | ||||
| Stephanie M. Kelly | |||||
| Chief Securities and Governance Counsel, Corporate Secretary | |||||
Date: July 22, 2026
NEWS RELEASE 
Mike Garrison to Retire from BD
FRANKLIN LAKES, N.J. (July 22, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.
Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD’s Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. Prior to joining BD in 2005, Garrison held various roles across R&D and marketing within the MedTech industry.
"Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions," said Tom Polen, Chairman, CEO and President of BD. "He has built strong teams, developed exceptional leaders and helped position our business for the future. We are grateful for Mike's leadership, partnership and many contributions to BD, and we wish him well in his retirement."
Garrison will remain in his role through the end of the fiscal year. A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Polen, streamlining the operating model and reflecting the segment’s strategic importance as a growth driver.
“It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world,” Garrison said. “I will always value the people, purpose and impact that have made my time at BD so meaningful, and I look forward to seeing the company continue to advance the future of care.”
# # #
About BD
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |||||
Media | Investors | ||||
Megan Dubrowski Senior Director, Executive Communications Megan.Dubrowski@bd.com | Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com | ||||